| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Fenquizone acts as a thiazide-like diuretic by blocking the reabsorption of sodium in the proximal tubule and the ascending branch of the loop of Henle. Its primary site of action is the diluting segment of the nephron cortex. By inhibiting sodium reabsorption, fenquizone increases the excretion of sodium and water, leading to diuresis and a reduction in blood volume and blood pressure.
|
|---|---|
| ln Vitro |
Fenquizone demonstrates diuretic activity in vitro by inhibiting sodium reabsorption in renal tubular cells. Its activity can be assessed using renal tubular cell cultures or isolated perfused kidney preparations. The compound's effects on sodium transport and urine output have been characterized in various in vitro models.
|
| ln Vivo |
Fenquizone is used in vivo as an orally active diuretic for the treatment of edema and hypertension. It has chronic antihypertensive effects, reducing blood pressure over time through its diuretic action. The compound's efficacy and safety have been evaluated in preclinical and clinical studies.
|
| Enzyme Assay |
Non-cellular enzyme assays for fenquizone are limited as it acts on ion transport mechanisms rather than through enzyme inhibition. Its effects on sodium transport can be assessed using membrane vesicle preparations or artificial membrane systems. The compound's physicochemical properties can be characterized using standard analytical techniques.
|
| Cell Assay |
In vitro cellular assays for fenquizone involve treating renal tubular cells with the compound and measuring its effects on sodium transport and cell function. The inhibition of sodium reabsorption can be assessed by measuring sodium flux using radioactive tracers (e.g., ²²Na) or by using ion-sensitive electrodes. The compound's effects on cell viability and function are also evaluated.
|
| Animal Protocol |
In vivo animal experiments with fenquizone are conducted in rodent models of hypertension and edema. Rats or other animals are treated with fenquizone via oral administration, and blood pressure, urine output, and electrolyte excretion are measured. The compound's antihypertensive and diuretic effects are assessed over time. Pharmacokinetic and toxicological studies are also conducted.
|
| ADME/Pharmacokinetics |
Fenquizone has a molecular weight of 337.78 and a molecular formula of C14H12ClN3O3S. It is a solid at room temperature with a melting point >296°C (dec.). Purity is typically ≥98%. The compound is typically stored at -20°C. It is soluble in DMSO and other organic solvents. Fenquizone is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Fenquizone is a research compound for laboratory use only and is not intended for human therapeutic or diagnostic use. As a thiazide-like diuretic, it may cause side effects similar to other diuretics, including electrolyte imbalances (hypokalemia, hyponatremia), dehydration, and metabolic abnormalities. Standard laboratory safety precautions should be followed when handling the compound.
|
| Additional Infomation |
Fenquizone belongs to the quinazoline class of drugs. Fenquizone is a quinazoline sulfonamide diuretic with a structure similar to metoprazine, exhibiting thiazide diuretic activity. As a thiazide diuretic, Fenquizone exerts its effect by blocking sodium reabsorption in the proximal tubule and the ascending limb of the loop of Henle. This leads to enhanced diuresis, thereby excreting chloride and sodium.
Fenquizone (MG-13054; CAS 20287-37-0) is a thiazide-like diuretic with chronic antihypertensive effects. It acts primarily on the diluting segment of the nephron cortex, similar to thiazide diuretics. Fenquizone is an orally active diuretic that has been studied for the treatment of edema and hypertension. The compound is available from various commercial suppliers for research applications. |
| Molecular Formula |
C21H29NO
|
|---|---|
| Molecular Weight |
311.469
|
| Exact Mass |
337.029
|
| CAS # |
20287-37-0
|
| PubChem CID |
68548
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.469g/cm3
|
| Index of Refraction |
1.644
|
| LogP |
4.089
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
530
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=C2C(C(=O)NC(C3C=CC=CC=3)N2)=CC=1S(N)(=O)=O
|
| InChi Key |
DBDTUXMDTSTPQZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12ClN3O3S/c15-10-7-11-9(6-12(10)22(16,20)21)14(19)18-13(17-11)8-4-2-1-3-5-8/h1-7,13,17H,(H,18,19)(H2,16,20,21)
|
| Chemical Name |
7-chloro-4-oxo-2-phenyl-2,3-dihydro-1H-quinazoline-6-sulfonamide
|
| Synonyms |
M.G. 13054 MG13054 MG-13054 Fenquizone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~296.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2106 mL | 16.0529 mL | 32.1058 mL | |
| 5 mM | 0.6421 mL | 3.2106 mL | 6.4212 mL | |
| 10 mM | 0.3211 mL | 1.6053 mL | 3.2106 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
